Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oral squamous cancer |
| ICD-0-3 | C06.9 |
| Methods | qPCR, Western blot, etc. |
| Sample | cell lines (OSCC3, SCC4, HSC3, CAL27) |
| Expression Pattern | down-regulated |
| Function Description | lncRNA ANRIL expression was signifcantly down-regulated in si-ANRIL-transfected HSC3, OSCC3 and SCC4 cells when compared with control cells.Down-regulated expression of lncRNA ANRIL inhibits OSCC cell proliferation and induces cell apoptosis in vitro. lncRNA ANRIL was involved in OSCC cell proliferation and sensitivity to cisplatin. |
| Pubmed ID | 29176691 |
| Year | 2017 |
| Title | Midkine derived from cancer associated fibroblasts promotes cisplatin-resistance via upregulation of the expression of lncRNA ANRIL in tumour cells |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for oral squamous cancer | OMIM COSMIC |